Singapore-based, Invida India which is part of the Singapore based leading speciality biopharmaceutical company, Invida, will expand its dermatology prescription portfolio in India. The company hopes to meet the needs of the rapidly expanding skin health sector in the region by bringing world class medicines and treatment solutions into the country.
It has now two products for the management of acne and Atopic Dermatitis. While Papulex is for Acne management, Atopiclair is recommended for Atopic Dermatitis.
Acne affects 80 per cent of adolescents and 20 per cent of adults, with more severity in men and higher levels of persistency in women. Studies show that acne triggers body image issues and low self-esteem in people and in certain cases can even lead to depression and severe anxiety.
Atopic dermatitis occurs primarily in infants and children, affecting 5-15 per cent of school children and 2-10 per cent of adults in India. However, lack of effective options has led to chronic skin conditions in many of these patients.
Invida India intends to change this by introducing vital treatment options and advanced skin health solutions to India to improve outcomes for patients in the areas of wound care, skin repair and dermatology, said Girdhar Balwani, managing director, Invida India.
Indian patients do not have access to the same treatment options as their Western counterparts. Now with the introduction of two products: Papulex which is an oil-free cream and Atopiclair cream it will cater to the needs of the patients.
According to the company, Papulex is an ideal for the long-term management of acne to reduce marks and prevent breakouts.. All the Papulex variants, including the Cleansing gel, Isocorrexion and Sunscreen, will be introduced over the next few months.
Atopiclair results in flare-remission providing symptomatic relief and control of atopic dermatitis. The product is clinically proven to reduce itch and the need for steroids. Atopic dermatitis affects up to 20 per cent of young children. Close on the heels of Atopiclair cream, the company will introduce Atopiclair lotion in October 2011.
Invida was set up in 2005, in a strategic partnership between Quintiles, the clinical research organization and , Temasek Holdings, and the Zuellig Group which is the largest pharmaceutical distribution and supply chain management network in Asia Pacific. Invida aims to become the leading provider of important healthcare brands and services in the region. It partners with multinational biopharmaceutical companies to commercialize products offering the advantage of a single point entry into Asia Pacific at any stage of the commercial value chain from regulatory approval and product launch to lifecycle management.